0 0 0 0 0 0 0.00473933649289089 0.000947867298578179
Sign Up Today X
Thanks for submitting the form.
Stockreport

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc. (EOLS)  More Company Research Source: Business Wire
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).“We are pleased to have submitted the final module of the PMA application,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. “This submission is a key fundamental milestone for Evolus and we look forward to our continued collaboration with the Agency in the upcoming thorough review process.”Evolus anticipates that the FDA’s review process will adhere to the standard timeline, with approval expected in the second half of 2025. The submission underscores Evolus’ commitment to bringing the dermal filler products to market and its readiness to meet regulatory requireme [Read more]
IMPACT SNAPSHOT EVENT TIME: EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
EOLS alerts
from News Quantified
EOLS
NEWS
EOLS
Earnings
EOLS
Analyst Actions
EOLS
SEC Filings
Stockreport

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc.  (EOLS) 
More Company Research Source: Business Wire
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).“We are pleased to have submitted the final module of the PMA application,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. “This submission is a key fundamental milestone for Evolus and we look forward to our continued collaboration with the Agency in the upcoming thorough review process.”Evolus anticipates that the FDA’s review process will adhere to the standard timeline, with approval expected in the second half of 2025. The submission underscores Evolus’ commitment to bringing the dermal filler products to market and its readiness to meet regulatory requireme [Read more]
IMPACT SNAPSHOT
EVENT TIME:
EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS